medigraphic.com
ISSN 1561-3038 (Print)

2015, Number 4

<< Back Next >>

Rev Cubana Med Gen Integr 2015; 31 (4)

Relationship between insulin resistance and polycystic ovary syndrome and its metabolic comorbidities

Hernández RJ, Licea PME

Language: Spanish
References: 49
Page: 383-394
PDF size: 129.03 Kb.


ABSTRACT

Introduction: Polycystic ovary syndrome is a disorder of multifactorial etiology, characterized by a heterogeneous clinical and subclinical, which sometimes makes handling and diagnosis difficult, and it is linked to several metabolic comorbidities especially those insulin resistant that may play a significant role.
Objective: Describe the relationship between insulin resistance and the genesis of polycystic ovarian syndrome and some of its metabolic comorbidities.
Conclusions: Insulin resistance is closely related to the genesis of polycystic ovary syndrome, as well as the development of some of its metabolic comorbidities (diabetes mellitus Type 2, dyslipidemia, nonalcoholic fatty liver disease and metabolic syndrome), which must be identified and timely and properly treated.


REFERENCES

  1. Martínez de Santelices A. Estrategia de abordaje clínico, genético y epidemiológico del Síndrome de ovarios Poliquísticos en pacientes atendidos en el Instituto Nacional de Endocrinología. Año 2013. Genética Comunitaria. [Internet]. 2014 [citado 2015 May 6]. Disponible en: http://geneticacomunitaria2014.sld.cu/index.php/geneticacomunitaria/2014/paper/vi ew/183

  2. De la Jara JF, Ortega C. Síndrome de ovario poliquístico. RevMexReprod. 2011;4:51-62.

  3. Pardo A. El misterio de los Ovarios Poliquísticos. Rev Cient Cienc Méd. 2012;15:26-28.

  4. Motta AB. Report of the Internationalal symposium: polycystic ovary syndrome: first Latin-American consensus. Int J ClinPract. 2010;64:544-57.

  5. Eshre TR, Group A. S. P. C. W. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. FertilSteril. 2004;81:19-25.

  6. Escobar CE. Síndrome de ovário poliquístico (SOP). XVII Curso de Actualización en Ginecología y Obstetricia: Una visión integral de la mujer. [Artículo en la Internet] 2012 [citado 19 Jun 2015]:224-35. Disponible en: http://aprendeenlinea.udea.edu.co/revistas/index.php/ginecologia_y_obstetricia/articl e/view/13731/12186

  7. Del Río M, Ramírez J, Cortés M, Martí G, Godoy A, Vigil P. Análisis de resistencia insulínica, tolerancia a la glucosa y testosterona en mujeres jóvenes con síndrome de ovario poliquístico agrupadas por índice de masa corporal. Rev Chil Obstet Ginecol. 2006;71:299-306.

  8. Pérez J, Méndez María, FuhrerJ. Síndrome de ovario poliquístico: presentación clínica, bioquímica y ultrasonográfica. Rev Chil Obstet Ginecol. 2003;68:471-6.

  9. Pinheiro A, Canaan F, Goncalves R. Insulinemia, ingesta alimentaria y metabolismo energético. Rev Chil Nutr. 2008;35:18-24.

  10. Chaila M, Sánchez M. Resistencia a la insulina: actualización, métodos mínimos de diagnóstico. Rev Argén Endocrinol Metab. 2005;42:90-114.

  11. Urdaneta J, Vera J, García J, Babel N, Contreras A. Insulino resistencia en mujeres infértiles. Rev Chil Obstet Ginecol. 2010;75:153-161.

  12. Ovies G, Domínguez E, Verdeja OL, Zamora H. Frecuencia y características clínicas, hormonales y ultrasonográficas sugestivas de síndrome de ovarios poliquísticos en un grupo de mujeres con síndrome metabólico. Rev Cuban Endocrinol. 2008 [citado 3 Jul 2015];19(1):[aprox. 5 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532008000100004

  13. Merchán A, Fidalgo AM. Diagnóstico de la resistencia a la insulina en mujeres con síndrome de ovario poliquísticos: Revisión sistemática. 2014 [citado 15 Jun 2015]. Disponible en: http://repository.urosario.edu.co/bitstream/handle/10336/10080/1015398605- 2015.pdf?sequence=1&isAllowed=y

  14. Alvarez F, Botella JI, San JL, Escobar HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. ArchInternMed. 2006;166:2081-6.

  15. Ibáñez L, López A, Díaz M, Maros MV. Endocrinology and gynaecology of girls and Women with Low Birth Weight. FetalDiagnTher. 2011;30:243-9.

  16. Shafiee MN, Chapman C, Barrett D, Abu J, Antiomo W. Reviewing the molecular mechanism whichincreasesendometrial cancer (EC) risk in women with polycystic ovary syndrome (PCOS): Time for paradigm shift? Gynecol Oncol. 2013;131:489-92.

  17. Moran L, Hutchinson S, Norman R, Teede H. Cambios en el estilo de vida para mujeres con síndrome de ovario poliquístico. Cochrane Database of Systematic Reviews 2011 Issue 2. Art. No.CD007506. doi: 10.1002/14651858.CD007506.

  18. Baptiste C, Battista M, Trottier A, Baillargeon J. Insulin and hyperandrogenism in women with polycystic ovary syndrome PCOS. J SteroidBiochem Mol Biol. 2010;122:42-52.

  19. Ovies G, Martínez de Santelices A, Monteagudo G, Sardiñas I. Bases genéticas del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2011;22:255-65.

  20. Hales CN, Barker DJ: The thrifty phenotype hypothesis. Br Med Bull. 2001;60:5-20.

  21. Barker DJ, Osmond C, Golding J, KuhD, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298:564-7.

  22. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ. 2000;320:967-71.

  23. Forsen T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med. 2000;133:176-182.

  24. Vilmann LS, Thisted E, Baket JL, Holm JC. Development of obesity and Polycystic Ovary Syndrome in Adolescents. Horm Res Pediatr. 2012;78:269-78.

  25. Paker VER, Semple RK. Genetic forms of severe insulin resistance: what endocrinologist should know? Eur J Endocrinol. 2013;169:R71-R80.

  26. Richard S, Legro MD. Obesity and PCOS: Implications for Diagnosis and Treatment. Reprod Med. 2012;30:496-506.

  27. Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J EndocrMetab. 2012;16:996-9.

  28. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution tometabolic disorders with polycystic ovary syndrome. FertilSteril. 2003;79:1358-64.

  29. Xita N, Tsatsoulis A. Review: Fetal programming of Polycystic Ovary Syndrome by androgen excess: experimental, clinical, and genetic association studies. J ClinEndocrinolMetab. 2006;91:1660-6.

  30. Carmina E, Orio F, Palomba S, Cascella T, Longo R, Colao A, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389-94.

  31. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome. Diabetes 1989;38:1165-74.

  32. Chaila M, Sánchez M. Resistencia a la insulina: actualización, métodos mínimos de diagnóstico. Rev Argen Endocrinol Metab. 2005;42:90-114.

  33. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91:456-88.

  34. Moran C, Arriaga M, Rodríguez G, Moran S. Obesity in Polycystic Ovary Syndrome. In Tech. [Internet] 2012 [citado 24 Jun 2015]. Disponible en: http://www.researchgate.net/profile/Segundo_Moran/publication/221925729_Obesity _in_Polycystic_Ovary_Syndrome/links/00b7d514b10d2a0830000000.pdf

  35. Aray MM, Arana G, Barriga N. Metformina como base del tratamiento del síndrome de ovario poliquístico. Rev Med Pre. 2014;4:15-21.

  36. Mollo JC, Montaño LA. Disruptores Endocrinos en el Plástico (Bisfenol A y Folatos). SCIENTIFICA 2013;11:19-22.

  37. González GL, Pérez RLT, Sánchez CH, Armendáriz CR, Girones CR, Fernández ÁJG, et al. Toxicidad del Bisfenol A (BPA): migración desde los envases a los alimentos. Aula de la Farmacia 2011;7:58-65.

  38. Vinther T, Norrman M, Ribel U, Huus K, Schlein M, Steensgaard D, et al. Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci. 2013;22:296-305.

  39. Valverde AM, Gonzalez-Rodriguez A. IRS2 and PTP1B: Two opposite modulators of hepatic insulin signalling. ArchPhysiolBiochem. 2011;117:105-15.

  40. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586-623.

  41. Bouchard C. Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord. 1995;12:S52-S59.

  42. López F, Cortés M. Obesidad y corazón. Revista Española de Cardiología 2011;64(2):140-9.

  43. Matthaei S, Stumvoll M, Kellerer M, Hans-Ulrich Häring HU. Pathophysiology and Pharmacological Treatment of Insulin Resistance. Endocr Rev. 2000;21:585-618.

  44. Targher G, DayCh P, Bonora E. Enfermedad del hígado graso no alcohólico. N Engl J Med. 2010;363:1341-50.

  45. Wellen KE. Obesity-induced inflammatory changes in adipose tissue. J ClinInvest. 2003;112:1785-8.

  46. Brea Á, Díaz Á, González P, Hernández A, Mantilla T, Millán J, et al. Consenso multidisciplinar sobre dislipidemia aterogénica. ClinInvestArterioescl. 2013;25:83-91.

  47. Millán J, Pedro Botet J, Pintó X. Riesgo vascular residual: Recomendaciones de la Iniciativa Española para la Reducción del Riesgo Residual. MedClin (Barc). 2010;135:165-71.

  48. Pineda CA. Síndrome metabólico: definición, historia, criterios. Colombia Médica 2013;39(1):96-106.

  49. Bonora E, Kiechl S, Willeint J, Oberhollenzer F, Egger G, Tagher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes. 1998;47:1643-9.




2020     |     www.medigraphic.com